CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 40 enrolled
Drug / intervention
Hyperbaric bupivacaine +1 moredrug
Likely dose
Hyperbaric bupivacaine 10 mg intrathecal or hyperbaric prilocaine 50 mg intrathecalAI-extracted
Key inclusion· 8
  • American Society of Anesthesiologists physical status less than III
  • Age 18-40 years
  • Body weight less than 110 kg
  • Height between 160 and 175 cm
Key exclusion· 12
  • Twin or multiple pregnancy
  • History of two or more prior cesarean sections
  • Diabetes or gestational diabetes
  • Placenta praevia

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02973048
NCT02973048Phase 3Completed

Hyperbaric Bupivacaine Versus Hyperbaric Prilocaine 2% for Cesarean Section Under Spinal Anesthesia: a Randomised Clinical Trial

Centre Hospitalier Universitaire Saint Pierre·interventional·Posted Nov 25, 2016·Updated Jul 2, 2020

In Brief

A Phase 3 clinical trial evaluating Hyperbaric bupivacaine and Hyperbaric prilocaine for Pregnant Women and 2 related conditions. Completed, enrolled 40 participants across 2 sites.

Detailed Summary

Over the past 15 years, cesarean delivery is most commonly performed under spinal anesthesia using hyperbaric bupivacaine which provides an adequate sensory and motor block. Despite effective surgical anesthesia, bupivacaine is associated with long duration motor block and dose-dependent maternal hypotension potentially harmful for the fetus. Prilocaine with its new 2% hyperbaric formulation (HP), developed recently, showed rapid onset of action and faster regression of motor block compared to other local anesthetics without noteworthy side-effects when used intrathecally. The aim of this randomized, multicenter, powered clinical trial is to investigate whether HP may be an efficient alternative to hyperbaric bupivacaine for scheduled caesarean delivery under spinal anesthesia, with more rapid rehabilitation and less adverse effects. Our hypothesis is that hyperbaric prilocaine offers shorter motor block and more rapid rehabilitation than bupivacaine.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBelgium
Collaborators--

Timeline

Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedNov 25, 2016
Enrollment StartMar 12, 2018
Primary CompletionNov 8, 2018
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 9.6 years ago

Interventions

Hyperbaric bupivacainedrug

The dose of 10 mg of hyperbaric bupivacaine will be administered to one of two groups intrathecally and the quality of sensory and motor block as well as side-effects will be observed at precise time points.

Hyperbaric prilocainedrug

The dose of 50 mg of hyperbaric prilocaine will be administered to one of two groups intrathecally and the quality of sensory and motor block as well as side-effects will be observed at precise time points.